Last reviewed · How we verify
Aprepitant and Dexamethasone
At a glance
| Generic name | Aprepitant and Dexamethasone |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile (PHASE2)
- 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC (PHASE2)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients (PHASE3)
- To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (PHASE3)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |